Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: What's the evidence? A systematic review with meta-analysis

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Van Den Broek, Alexandra J ^a   Schmidt, Marjanka K ^a   Van 't Veer, Laura J ^a   Tollenaar, Rob A E M ^b   Van Leeuwen, Flora E ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE SPECIFIC SURVIVAL; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; LONG TERM SURVIVAL; METASTASIS FREE SURVIVAL; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROPHYLACTIC SURGICAL PROCEDURE; RECURRENCE FREE SURVIVAL; SHORT TERM SURVIVAL; SYSTEMATIC REVIEW; TUMOR SUPPRESSOR GENE; BREAST TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; RISK FACTOR; SURVIVAL RATE;

BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MUTATION; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 84929458975     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120189     Document Type: Article

References (66)

1. Robson ME. Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer. Cancer Control. 2002; 9: 457-465. PMID: 12514563
2. Honrado E, Osorio A, Palacios J, Benitez J. Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. Oncogene. 2006; 25: 5837-5845. PMID: 16998498
3. Phillips KA. Current perspectives on BRCA1-and BRCA2-associated breast cancers. Intern Med J. 2001; 31: 349-356. PMID: 11529589
4. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer. 2004; 4: 665-676. PMID: 15343273
5. Porter DE, Cohen BB, Wallace MR, Smyth E, Chetty U, Dixon JM, et al. Breast cancer incidence, penetrance and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br J Surg. 1994; 81: 1512-1515. PMID: 7820489
6. Monninkhof EM, Elias SG, Vlems FA, van der Tweel I, Schuit AJ, Voskuil DW, et al. Physical activity and breast cancer: a systematic review. Epidemiology. 2007; 18: 137-157. PMID: 17130685
7. Johannsson OT, Ranstam J, Borg A, Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol. 1998; 16: 397-404. PMID: 9469321
8. Plakhins G, Irmejs A, Gardovskis A, Subatniece S, Liepniece-Karele I, Purkalne G, et al. Underestimated survival predictions of the prognostic tools Adjuvant! Online and PREDICT in BRCA1-associated breast cancer patients. Fam Cancer. 2013.
9. Wagner TM, Moslinger RA, Muhr D, Langbauer G, Hirtenlehner K, Concin H, et al. BRCA1-related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics. Int J Cancer. 1998; 77: 354-360. PMID: 9663595
10. Gaffney DK, Brohet RM, Lewis CM, Holden JA, Buys SS, Neuhausen SL, et al. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol. 1998; 47: 129-136. PMID: 9683359
11. Cortesi L, Masini C, Cirilli C, Medici V, Marchi I, Cavazzini G, et al. Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer. BMC Cancer. 2010; 10: 90. doi: 10.1186/1471-2407-10-90 PMID: 20219108
12. Hagen AI, Tretli S, Maehle L, Apold J, Veda N, Pål Møller, et al. Survival in Norwegian BRCA1 mutation carriers with breast cancer. Hered Cancer Clin Pract. 2009; 7: 7. doi: 10.1186/1897-4287-7-7 PMID: 19366445
13. Carroll PA, Nolan C, Clarke R, Farrell M, Gleeson N, Boyle T, et al. Surgical management of an Irish cohort of BRCA-mutation carriers. Breast. 2011; 20: 419-423. doi: 10.1016/j.breast.2011.04.005 PMID: 21570850
14. Dersimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-188. PMID: 3802833
15. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001; 323: 101-105. PMID: 11451790
16. Ansquer Y, Gautier C, Fourquet A, Asselain B, Stoppa-Lyonnet D. Survival in early-onset BRCA1 breast-cancer patients. Institut Curie Breast Cancer Group. Lancet. 1998; 352: 541. PMID: 9716061
17. Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol. 2011; 29: 3739-3746. doi: 10.1200/JCO.2011.35.2682 PMID: 21900106
18. Bayraktar S, Gutierrez-Barrera AM, Liu D, Tasbas T, Akar U, Litton JK, et al. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat. 2011; 130: 145-153. doi: 10.1007/s10549-011-1711-z PMID: 21830012
19. Bonadona V, Dussart-Moser S, Voirin N, Sinilnikova OM, Mignotte H, Mathevet P, et al. Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review. Breast Cancer Res Treat. 2007; 101: 233-245. PMID: 17061047
20. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, vd Ouweland A, Menke-Pluymers MB, Bartels CC, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1-and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer. 2007; 43: 867-876. PMID: 17307353
21. Budroni M, Cesaraccio R, Coviello V, Sechi O, Pirino D, Cossu A, et al. Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia. BMC Cancer. 2009; 9: 62. doi: 10.1186/1471-2407-9-62 PMID: 19232099
22. Chappuis PO, Kapusta L, Begin LR, Wong N, Brunet JS, Narod SA, et al. Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol. 2000; 18: 4045-4052. PMID: 11118465
23. Chappuis PO, Donato E, Goffin JR, Wong N, Begin LR, Kapusta LR, et al. Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. Ann Oncol. 2005; 16: 735-742. PMID: 15802279
24. Chiappetta G, Ottaiano A, Vuttariello E, Monaco M, Galdiero F, Gallipoli A, et al. HMGA1 protein expression in familial breast carcinoma patients. Eur J Cancer. 2010; 46: 332-339. doi: 10.1016/j.ejca.2009.10.015 PMID: 19896837
25. Eccles D, Simmonds P, Goddard J, Coultas M, Hodgson S, et al. Familial breast cancer: an investigation into the outcome of treatment for early stage disease. Fam Cancer. 2001; 1: 65-72. PMID: 14573999
26. Eerola H, Vahteristo P, Sarantaus L, Kyyronen P, Pyrhonen S, et al. Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: a relative survival analysis from Finland. Int J Cancer. 2001; 93: 368-372. PMID: 11433401
27. Einbeigi Z, Bergman A, Kindblom LG, Martinsson T, Meis-Kindblom JM, Nordling M, et al. A founder mutation of the BRCA1 gene in Western Sweden associated with a high incidence of breast and ovarian cancer. Eur J Cancer. 2001; 37: 1904-1909. PMID: 11576847
28. El Tamer M, Russo D, Troxel A, Bernardino LP, Mazziotta R, Estabrook A, et al. Survival and recurrence after breast cancer in BRCA1/2 mutation carriers. Ann Surg Oncol. 2004; 11: 157-164. PMID: 14761918
29. Ellberg C, Jonsson G, Olsson H. Can a phenotype for recessive inheritance in breast cancer be defined? Fam Cancer. 2010; 9: 525-530. doi: 10.1007/s10689-010-9355-4 PMID: 20549370
30. Foulkes WD, Wong N, Brunet JS, Begin LR, Zhang JC, Martinez JJ, et al. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res. 1997; 3: 2465-2469. PMID: 9815648
31. Goffin JR, Chappuis PO, Begin LR, Wong N, Brunet JS, et al. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. Cancer. 2003; 97: 527-536. PMID: 12548593
32. Goffin JR, Straume O, Chappuis PO, Brunet JS, Begin LR, Hamel N, et al. Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer. Br J Cancer. 2003; 89: 1031-1034. PMID: 12966421
33. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011; 17: 1082-1089. doi: 10.1158/1078-0432.CCR-10-2560 PMID: 21233401
34. Goode EL, Dunning AM, Kuschel B, Healey CS, Day NE, Ponder BAJ, et al. Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res. 2002; 62: 3052-3057. PMID: 12036913
35. Goodwin PJ, Phillips KA, West DW, Ennis M, Hopper JL, John EM, et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. J Clin Oncol. 2012; 30: 19-26. doi: 10.1200/JCO.2010.33.0068 PMID: 22147742
36. Hamann U, Sinn HP. Survival and tumor characteristics of German hereditary breast cancer patients. Breast Cancer Res Treat. 2000; 59: 185-192. PMID: 10817354
37. Heikkinen T, Karkkainen H, Aaltonen K, Milne RL, Heikkila P, Aittomäki K, et al. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin Cancer Res. 2009; 15: 3214-3222. doi: 10.1158/1078-0432.CCR-08-3128 PMID: 19383810
38. Kirova YM, Savignoni A, Sigal-Zafrani B, de La Rochefordiere A, Salmon RJ, et al. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature. Breast Cancer Res Treat. 2010; 120: 119-126. doi: 10.1007/s10549-009-0685-6 PMID: 20033769
39. Lee JS, Wacholder S, Struewing JP, McAdams M, Pee D, Brody LC, et al. Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 1999; 91: 259-263. PMID: 10037104
40. Lee LJ, Alexander B, Schnitt SJ, Comander A, Gallagher B, et al. Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer. 2011; 117: 3093-3100. doi: 10.1002/cncr.25911 PMID: 21264845
41. Loman N, Johannsson O, Bendahl P, Dahl N, Einbeigi Z, Gerdes A-M, et al. Prognosis and clinical presentation of BRCA2-associated breast cancer. Eur J Cancer. 2000; 36: 1365-1373. PMID: 10899649
42. Moller P, Borg A, Evans DG, Haites N, Reis MM, Vasen H, et al. Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. Int J Cancer. 2002; 101: 555-559. PMID: 12237897
43. Moller P, Evans DG, Reis MM, Gregory H, Anderson E, Maehle L, et al. Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int J Cancer. 2007; 121: 1017-1020. PMID: 17471561
44. Musolino A, Bella MA, Bortesi B, Michiara M, Naldi N, Zanelli P, et al. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study. Breast. 2007; 16: 280-292. PMID: 17257844
45. Nisman B, Allweis T, Kaduri L, Maly B, Gronowitz S, et al. Serum thymidine kinase 1 activity in breast cancer. Cancer Biomark. 2010; 7: 65-72. doi: 10.3233/CBM-2010-0148 PMID: 21178264
46. Pierce LJ, Strawderman M, Narod SA, Oliviotto I, Eisen A, Dawson L, et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol. 2000; 18: 3360-3369. PMID: 11013276
47. Pierce LJ, Levin AM, Rebbeck TR, Ben David MA, Friedman E, Solin LJ, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006; 24: 2437-2443. PMID: 16636335
48. Plakhins G, Irmejs A, Gardovskis A, Subatniece S, Rozite S, Bitina M, et al. Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia. BMC Med Genet. 2011; 12: 147. doi: 10.1186/1471-2350-12-147 PMID: 22032251
49. Rennert G, Bisland-Naggan S, Barnett-Griness O, Bar-Joseph N, Zhang S, Rennert HS, et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med. 2007; 357: 115-123. PMID: 17625123
50. Rijnsburger AJ, Obdeijn IM, Kaas R, Tilanus-Linthorst MM, Boetes C, Loo CE, et al. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol. 2010; 28: 5265-5273. doi: 10.1200/JCO.2009.27. 2294 PMID: 21079137
51. Robson M, Gilewski T, Haas B, Levin D, Borgen P, et al. BRCA-associated breast cancer in young women. J Clin Oncol. 1998; 16: 1642-1649. PMID: 9586873
52. Robson M, Levin D, Federici M, Satagopan J, Bogolminy F, Heerdt A, et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst. 1999; 91: 2112-2117. PMID: 10601383
53. Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 2004; 6: R8-R17. PMID: 14680495
54. Seynaeve C, Verhoog LC, van de Bosch LM, van Geel AN, Menke-Pluymers M, Meijers-Heijboer EJ, et al. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer. 2004; 40: 1150-1158. PMID: 15110878
55. Soumittra N, Meenakumari B, Parija T, Sridevi V, Nancy KN, Swaminathan R, et al. Molecular genetics analysis of hereditary breast and ovarian cancer patients in India. Hered Cancer Clin Pract. 2009; 7: 13. doi: 10.1186/1897-4287-7-13 PMID: 19656415
56. Stoppa-Lyonnet D, Ansquer Y, Dreyfus H, Gautier C, Gauthier-Villars M, Bourstyn E, et al. Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol. 2000; 18: 4053-4059. PMID: 11118466
57. Verhoog LC, Brekelmans CT, Seynaeve C, van den Bosch LM, Dahmen G, van Geel AN, et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet. 1998; 351: 316-321. PMID: 9652611
58. Verhoog LC, Brekelmans CT, Seynaeve C, Dahmen G, van Geel AN, Bartels CC, et al. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol. 1999; 17: 3396-3402. PMID: 10550133
59. Veronesi A, de Giacomi C, Magri MD, Lombardi D, Zanetti M, Scuderi C, et al. Familial breast cancer: characteristics and outcome of BRCA 1-2 positive and negative cases. BMC Cancer. 2005; 5: 70. PMID: 15996267
60. Vinodkumar B, Syamala V, Abraham EK, Balakrishnan R, Ankathil R. Germline BRCA1 mutation and survival analysis in familial breast cancer patients in Kerala; South India. J Exp Clin Cancer Res. 2007; 26: 329-336. PMID: 17987791
61. Xu J, Wang B, Zhang Y, Li R, Wang Y, Zhang S, et al. Clinical implications for BRCA gene mutation in breast cancer. Mol Biol Rep. 2012; 39: 3097-3102. doi: 10.1007/s11033-011-1073-y PMID: 21691706
62. Tryggvadottir L, Olafsdottir EJ, Olafsdottir GH, Sigurdsson H, Johannsson OT, Bjorgvinsson E, et al. Tumour diploidy and survival in breast cancer patients with BRCA2 mutations. Breast Cancer Res Treat. 2013; 140: 375-384. doi: 10.1007/s10549-013-2637-4 PMID: 23857704
63. Huzarski T, Byrski T, Gronwald J, Gorski B, Domagala P, Cybulski C, et al. Ten-Year Survival in Patients With BRCA1-Negative and BRCA1-Positive Breast Cancer. J Clin Oncol. 2013.
64. Bordeleau L, Panchal S, Goodwin P. Prognosis of BRCA-associated breast cancer: a summary of evidence. Breast Cancer Res Treat. 2010; 119: 13-24. doi: 10.1007/s10549-009-0566-z PMID: 19789974
65. Lee EH, Park SK, Park B, Kim SW, Lee MH, Ahn SH, et al. Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: a systematic review and meta-analysis. Breast Cancer Res Treat. 2010; 122: 11-25. doi: 10.1007/s10549-010-0859-2 PMID: 20376556
66. Foulkes WD. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer. 2006; 5: 135-142. PMID: 16736282